2022 ASMBS and IFSO Indications for Metabolic and Bariatric Surgery

Front

1 of 3 · Front

📘 GuidelineCh 11 · Bariatric & Metabolic Surgery

2022 ASMBS and IFSO Indications for Metabolic and Bariatric Surgery

In one breath

The 2022 ASMBS/IFSO indications for metabolic and bariatric surgery: recommended at BMI above 35 kg/m² regardless of comorbidity, to be considered at BMI 30–34.9 kg/m² with metabolic disease, with lower thresholds for Asian populations.

Edition2022

Issued byAmerican Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO)

Place of issueInternational

PublishedObesity Surgery · 2023;33(1):3–14

⏳ Pending verification

FACE COLOURS Front — the summary · Back 1 — what it covers + key recommendations · Back 2 — evidence, changes + source

Back 1

2 of 3 · Back 1

Back colours mark the reading sections — the chapter colour is the band and chip.

§1 · What it covers

This guideline covers indications for metabolic and bariatric surgery (MBS), including BMI thresholds, metabolic disease, Asian BMI thresholds, adolescents, and long-term follow-up. Relevant to upper-GI practice because RYGB and sleeve gastrectomy materially affect GERD and foregut decision-making.

Applies to: Adults with obesity and selected adolescents; Asian populations receive lower BMI thresholds.

§2 · Key recommendations

MBS is recommended for BMI >35 kg/m² regardless of comorbidity severity.
should be considered for BMI 30–34.9 kg/m² with metabolic disease or inadequate durable response to nonsurgical therapy.
and Asian thresholds should be adjusted so BMI >25 suggests clinical obesity and BMI >27.5 supports offering MBS.
The statement supports long-term multidisciplinary follow-up.
It is not a dedicated GERD guideline, but RYGB is often preferred over sleeve when obesity and medically refractory GERD coexist in other society algorithms.

FACE COLOURS Front — the summary · Back 1 — what it covers + key recommendations · Back 2 — evidence, changes + source

Back 2

3 of 3 · Back 2

Back colours mark the reading sections — the chapter colour is the band and chip.

§3 · Evidence & grading

The source record does not reproduce this guideline's evidence framework or grading: 'Evidence/grade not fully reproduced in report block; consult original source' Per-recommendation certainty and strength: Not yet established — pending verification.

§4 · What changed in this edition

Not yet established — pending verification.

§5 · Source & working link

Eisenberg D, et al. 2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) Indications for Metabolic and Bariatric Surgery. Obes Surg. 2023;33(1):3–14. doi:10.1007/s11695-022-06332-1 · PMID 36336720.

Publisher — the record's original_url, carried verbatim ↗DOI — 10.1007/s11695-022-06332-1 ↗PubMed — PMID 36336720 ↗

Link check 2026-11-11: DOI and PubMed (PMID 36336720) fetched live — title, journal, volume and pages match the record. The record's original_url fetched HTTP 200 but resolves to a DIFFERENT guideline (a multi-society GERD consensus page on sages.org), not to this statement — a source-record error, flagged here and carried verbatim per spec; rely on the DOI/PubMed rows.

Source: Tamer-supplied guideline index, intake 2026-11-10 (record #21, Domain 02) · Card built 2026-11-11 (Wave D) from the record itself; the §5.2 verification pass (UpToDate + Medscape → Perplexity → Tamer decision) has not yet run on this card. ⚑ Conflict flag on the source record — documented cross-society disagreement (intake DOCX Table 2): Bariatric eligibility — ASMBS/IFSO 2022 vs NICE NG246 2025/2026. Unresolved — pending the verification pass (UpToDate + Medscape → Perplexity → Tamer decision).

FACE COLOURS Front — the summary · Back 1 — what it covers + key recommendations · Back 2 — evidence, changes + source

gl-div11-asmbs-ifso-indications-2022-d02GS.code · Guidelines

More in Division 11 · Bariatric & Metabolic Surgery

📘 GuidelineCh 11 · Bariatric & Metabolic Surgery⏳ Pending verification

2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): Indications for Metabolic and Bariatric Surgery

The 2022 ASMBS/IFSO indications statement (Domain 09 filing of the same guideline as the Domain 02 record): metabolic and bariatric surgery recommended at BMI above 35 kg/m², to be considered at BMI 30–34.9 kg/m² with metabolic disease, with adjusted Asian thresholds.

2022 · American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO)

📘 GuidelineCh 11 · Bariatric & Metabolic Surgery⏳ Pending verification

Scientific Evidence for the Updated Guidelines on Indications for Metabolic and Bariatric Surgery (IFSO/ASMBS)

The 2024 evidence update behind the ASMBS/IFSO indications: a systematic report on 13 criteria — BMI thresholds, Asian populations, diabetes, age, adolescents, safety and long-term outcomes — finding the evidence for expanded eligibility strengthened, though several questions rest on observational data.

2024 Evidence Update · International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) and ASMBS

📘 GuidelineCh 11 · Bariatric & Metabolic Surgery⏳ Pending verification

NICE NG246 (England and Wales-facing national guidance)

NICE guideline NG246 on overweight and obesity: specialist multidisciplinary assessment first, bariatric surgery considered inside the defined NHS pathway after appropriate assessment and prior weight-management approaches, with lower BMI thresholds for several ethnic groups.

NG246 — 2025 (updated 2026) · National Institute for Health and Care Excellence (NICE)